AI Rivals Unite on Bioweapon Prevention Push
Benzinga reported Thursday that executives from OpenAI, Google DeepMind, and Anthropic have joined a broad coalition calling on U.S. lawmakers to mandate bioweapon screening. The group, numbering close to 75 signatories, is pressing Congress to act during its current session. Their concern centers on AI’s growing ability to erode the technical barriers that once slowed bad actors.
AI Is Lowering the Know-How Barrier
The coalition argues that advanced AI systems can now answer highly specialized laboratory questions. That capability once required years of scientific training to access. According to signatories, people without formal scientific backgrounds can now replicate complex lab procedures by querying AI tools. The group says this collapse of the so-called “know-how barrier” makes federal biosecurity rules increasingly urgent.
The letter acknowledges that near-term risk assessments remain mixed among researchers. Even so, signatories warn that the window for preventive policy action is narrowing. The coalition includes Nobel laureates, Turing Award recipients, university scientists, and former senior U.S. national security officials.
What the Coalition Is Asking For
The group’s proposal centers on mandatory synthetic nucleic acid purchase screening. It would require DNA synthesis companies and laboratory equipment makers to vet incoming orders. Firms would need to verify buyer legitimacy, flag sequences of concern, and retain records for potential investigations.
Signatories noted that the existence of traceability itself acts as a deterrent. Many large synthesis providers already conduct voluntary checks, the letter acknowledged. The coalition argued that voluntary compliance is insufficient without a uniform federal baseline. A national standard, they said, would prevent a fragmented state-by-state regulatory landscape from emerging.
A Rare Moment of Industry Alignment
The coalition framed the effort as an unusual convergence of stakeholders who frequently disagree. AI companies, biosecurity specialists, and biotech executives rarely coordinate public policy positions. The letter described the moment as a genuine opportunity for bipartisan legislative action.
The signatories urged Congress not to squander that alignment. Decisive federal action, the group argued, would preserve legitimate research workflows while closing a meaningful gap in the biotech supply chain. Companies that already screen voluntarily expressed support for the consistent standards a federal rule would create.
The push arrives as lawmakers face mounting pressure to regulate AI’s role in sensitive scientific domains. No specific bill has yet been named as the vehicle for the proposed requirements.
Read Next: Sam Altman Backs Bipartisan Push to Regulate AI in High-Risk Sectors
